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ABSTRACT
Objective Systemic sclerosis (SSc) is a systemic
autoimmune disease with high morbidity and significant
mortality. There is a great need of predictors that would
allow risk stratification of patients with SSc and ultimately
initiation of treatment early enough to ensure optimal
clinical results. In this study, we evaluated whether a
history of digital ulcers (HDU) at presentation may be a
predictor of vascular outcomes and of overall clinical
worsening and death in patients with SSc.
Methods Patients from the EULAR Scleroderma Trials
and Research (EUSTAR) database, satisfying at inclusion
the 1980 American College of Rheumatology
classification criteria for SSc, who had a follow-up of at
least 3 years since baseline or who have died, were
included in the analysis. HDU at presentation as a
predictor of disease worsening or death was evaluated by
Cox proportional hazards regression analysis.
Results 3196 patients matched the inclusion criteria
(male sex 13.2%, 33.4% diffuse subset). At presentation,
1092/3196 patients had an HDU (34.1%). In
multivariable analysis adjusting for age, gender and all
parameters considered potentially significant, HDU was
predictive for the presence of active digital ulcers (DUs) at
prospective visits (HR (95% CI)): 2.41 (1.91 to 3.03),
p<0.001, for an elevated systolic pulmonary arterial
pressure on heart ultrasound (US-PAPs):1.36 (1.03 to
1.80), p=0.032, for any cardiovascular event (new DUs,
elevated US-PAPs or LV failure): 3.56 (2.26 to 5.62),
p<0.001, and for death (1.53 (1.16 to 2.02), p=0.003).
Conclusions In patients with SSc, HDU at presentation
predicts the occurrence of DUs at follow-up and is
associated with cardiovascular worsening and decreased
survival.
INTRODUCTION
Systemic sclerosis (SSc) is characterised by skin and
internal organ fibrosis, in association with small
vessel dysfunction and obliterative changes. While
fibrosis is the hallmark of SSc, growing evidence
supports the role of the microvasculopathy as the
primary pathogenetic event.1 It has been shown
that SSc is the connective tissue disease with the
highest mortality.2 In fact, patients with SSc are at
risk for developing life-threatening internal organ
involvement such as interstitial lung disease (ILD),
pulmonary hypertension, heart failure, severe
gastrointestinal involvement and scleroderma renal
crisis.3 Therefore, it is imperative to diagnose and
to treat the disease and the involvement of internal
organs as early as possible. However, in clinical
practice this is a difficult task, in particular because
reliable predictors or biomarkers of outcome are
still missing. At present, the main strategy is to
screen regularly for internal organ involvement,
with a frequency that has not been standardised
yet. Early aggressive treatment may be of crucial
importance, but because of toxicity it is currently
restricted to patients in whom clinically significant
visceral involvement, in most cases with irreversible
damage, has already been documented. For this
reason, in SSc, there is an urgent need to identify
and validate predictors of disease worsening.
Digital ulcers (DUs) occur rather early in the
course of SSc4 5 and are a good candidate as clin-
ical predictor of disease evolution. In SSc, several
cross-sectional studies have found an association
between the presence of DUs and more severe
disease, as defined by the following: more extensive
skin involvement in the SSc diffuse cutaneous
subset (dc-SSc),4 6 7 the presence of pulmonary
arterial hypertension,7 and of ILD.6 8 Another pro-
spective study showed that patients with SSc with
DUs developed organ involvement approximately
2–3 years earlier than patients without DUs.7
Recently, it has been shown that DUs may herald
internal organ involvement also in patients with
very early SSc.5
These interesting results need to be confirmed in
larger cohorts. The EULAR Scleroderma Trials and
Research (EUSTAR) cohort is currently the largest
prospective SSc cohort in the world.9 10 The aim
of the present work was to use the EUSTAR data-
base to test the hypothesis that a history of DUs
(HDU) at the patient’s first presentation may
predict a worse prognosis characterised by a worse
disease course and death.
METHODS
All patients satisfying at inclusion the 1980
American Rheumatology Association classification
criteria for SSc11 and with a follow-up of at least
3 years since inclusion, or who died (the baseline
visit being registered before 1 January 2009), were
extracted from the EUSTAR database. The follow-
ing outcomes have been defined as indicating a
severe course of the disease: active DUs observed at
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prospective visits; recent DUs, defined as DUs reported by the
patient at prospective visits as having occurred since the last
visit; skin involvement worsening, defined as an increase of the
modified Rodnan skin score (mRSS)12 with at least five points
and at least 20% compared with baseline; severe ILD, defined
by a forced vital capacity (FVC) <50% of the predicted value,
at any visit; severely decreased alveolo-capillary diffusion of
carbon monoxide (DLCO) of any cause, defined as a DLCO
<40% of the predicted value, at any visit; elevated systolic pul-
monary arterial pressure >40 mm Hg as assessed by power
Doppler heart ultrasound examination (US-PAPs), at any visit;
heart failure, defined by an LVEF <50%, at any visit; sclero-
derma renal crisis (excluding the patients in which there is a
history of SSc renal crisis at baseline); and overall cardiovascular
events, defined as the occurrence of any of the following: recent
DUs (as already specified), US-PAPs >40 mm Hg or LVEF
<50%. All cause-mortality has also been investigated as an
outcome.
Statistical analysis
The analysis was carried out with the statistics softwares IBM
SPSS V.20.0 and SAS V.9.2. A p value <0.05 was considered as
statistically significant. Comparisons between groups were per-
formed with the χ2 test (for categorical variables) or with the
independent samples t test (for numeric variables).
HDU at presentation and all baseline parameters recorded in
the EUSTAR minimal, essential data set (MEDS), potentially
influencing each of the outcomes described above, were evalu-
ated by Kaplan–Meier survival plots and by age-adjusted and
gender-adjusted Cox proportional hazards regression analysis (as
categorical, dichotomous variables). Further, HDU at inclusion,
age, gender and all baseline MEDS parameters considered
potentially significant predictors were introduced in the multi-
variable analysis.
RESULTS
Following the inclusion criteria, 3207 patients were selected
from the EUSTAR database. Of these, we had baseline data
about the presence or absence of HDU in 3196 patients, of
which 1092 (34.1%) were positive for HDU. The demographic
and clinical features of the study cohort are shown in table 1.
The follow-up for the entire cohort was 5.0±2.2 years and
451 deaths of all causes were recorded up to February 2012.
The time to death since the onset of Raynaud’s phenomenon
(RP) was 17.3±11.3 years and since the first non-Raynaud
symptom 8.9±8.6 years. Death due to SSc was mentioned in
288 cases, non-SSc related death—in 85 cases while 78 deaths
remained unclassified.
Patients with HDU at baseline (HDU-positive) were further
compared by χ2 test with patients negative for HDU at inclusion
(HDU-negative) in regard to baseline variables as well as to out-
comes (table 1). HDU-positive patients had a significantly more
frequent occurrence of both active DUs and recent DUs at pro-
spective visits, as defined in the Methods section. Also, deterior-
ation of FVC, DLCO and LVEF, as well as elevated US-PAPs,
overall cardiovascular events, and death, were more frequent
outcomes in HDU-positive patients. There was no difference in
occurrence of skin involvement worsening and of scleroderma
renal crisis between groups.
Cox proportional hazards analysis of HDU as a predictor
of the selected outcomes, adjusted for age and gender
In age-adjusted and gender-adjusted analysis, HDU at inclusion
in the cohort was predictive for both active and recent DUs at
prospective visits (table 2), also for elevated US-PAPs, overall
cardiovascular events and death of all causes (tables 3–5). We
have not explored pulmonary arterial hypertension defined by
right heart catheterisation as an outcome, because of the small
number of patients who had performed this investigation (96 of
Table 1 Demographic data and outcomes in patients with and without a history of digital ulcers (DUs) at inclusion (n=3196)
Demographic data HDU+ (n=1092) HDU− (n=2104) All patients (n=3196) p Value*
Female sex 83.8% 88.3% 86.8% 0.002
Age (years), mean±SD 52.5±14.0 55.6±13.2 54.6±13.6 <0.001
Disease duration (years)
Since first non-Raynaud symptom, mean±SD 8.8±8.0 7.7±7.4 8.1±7.7 <0.001
Since onset of Raynaud’s, mean±SD 12.4±11.0 12.2±11.3 12.3±11.2 0.564
Diffuse cutaneous subset 41.7% 29.1% 33.4% <0.001
Anti-centromere positive 28.0% 38.0% 34.6% <0.001
Anti-topoisomerase I positive 42.4% 28.9% 33.5% <0.001
Raynaud’s phenomenon present 98.2% 95.7% 96.5% <0.001
Outcomes
DUs reported since last visit 77.2% 34.1% 48.3% <0.001
Active DUs at prospective visits 34.6% 14.0% 20.6% <0.001
Skin involvement worsening 40.1% 41.5% 41.0% 0.508
FVC <50% predicted 5.4% 3.0% 3.8% 0.004
DLCO<40% predicted 20.1% 15.4% 17.0% 0.001
LVEF<50% 5.5% 3.6% 4.2% 0.073
Elevated US-PAPs 39.7% 34.5% 36.2% 0.004
Scleroderma renal crisis 1.7% 1.6% 1.6% 0.887
Death 19.7% 11.4% 14.1% <0.001
See the Methods section for definition of outcomes.
HDU+/HDU−, patients positive/negative for a history of DUs at baseline.
FVC <50% predicted, lung forced vital capacity <50% of the predicted value; DLCO<40% predicted, lung CO diffusion <40% of the predicted value; Elevated US-PAPs, a systolic
pulmonary arterial pressure >40 mm Hg as measured by power Doppler heart ultrasound examination. For all these parameters values are considered at any visit including baseline.
*Significance of the difference between HDU+ and HDU− patients, by χ2 test (for categorical variables) or independent samples t test (for numeric variables).
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3196). Figure 1 illustrates by Kaplan–Meier survival plots the
relationship between HDU at presentation and these outcomes.
Furthermore, HDU at baseline was found to be predictive for
severe ILD with an HR and 95% CI of 1.71 (1.13 to 2.59),
p=0.011 and for severely decreased DLCO with an HR (95%
CI) of 1.42 (1.19 to 1.70), p<0.001. HDU was not predictive
for worsening of skin involvement, scleroderma renal crisis and
cardiac worsening defined as an LVEF of <50%. In all models,
both adjusting for disease duration since first non-Raynaud’s
symptom, or since RP onset, instead of age, led to similar results
(data not shown).
Cox proportional hazards analysis of HDU as a predictor of
the selected outcomes, adjusted for age, gender and all
clinically significant baseline covariates
The results of the Cox proportional hazards regression analysis
adjusted for age, gender and all potentially significant predictors
of each outcome are shown in tables 2–5. HDU at baseline was
predictive for active and for recent DUs, also for elevated
US-PAPs, for overall cardiovascular events and for death. In this
multivariable analysis, the relationship between HDU at baseline
and the outcomes ‘severe ILD’ and ‘severely decreased DLCO’
was not statistically significant.
DISCUSSION
Our data, derived from the largest prospective SSc cohort, show
that patients with HDU are prone to develop not only more
new DUs, but an elevated US-PAPs and overall cardiovascular
events as well, and are characterised by a decreased survival.
As expected, HDU at the first visit was found to be the stron-
gest predictor for the occurrence/reoccurrence of DUs at pro-
spective visits, with the highest HR among all covariates in the
multivariable Cox proportional hazards models. We have been
able to include as covariates several other baseline parameters
that have been shown in other studies to be predictive for DUs,
such as male gender, dcSSc subset, elevated US-PAPs, and anti-
topoisomerase I antibodies (ATA), thus demonstrating that HDU
is a stronger predictor for new DUs than any other of these.6 7
Recently, biomarkers such as increased serum placental growth
factor (PlGF) levels and low circulating endothelial progenitor
cells (EPCs) levels have been shown to predict the subsequent
development of DUs in patients with SSc.13 Noteworthy, in the
multivariable model which also included high PlGF, low EPCs
and high erythrocyte sedimentation rate (ESR) as independent
predictors of new DUs, HDU was the predictor with the highest
HR.13 The results of our multivariable analysis confirm once
more that for clinical trials aiming at DU prevention, HDU is the
Table 3 Predictors of elevated pulmonary arterial pressure of all causes, estimated by power Doppler heart ultrasound examination (systolic




for age and gender p Value
HR (95% CI)
Analysis adjusted
for age, gender and
all listed covariates p Value
HDU 1.32 (1.17 to 1.49) <0.001 1.36 (1.03 to 1.80) 0.032
Dyspnoea (clinically significant) 2.19 (1.25 to 2.47) <0.001 1.85 (1.32 to 2.58) <0.001
Lung function restrictive defect 2.19 (1.95 to 2.47) <0.001 1.89 (1.38 to 2.60) <0.001
DLCO<80% predicted 2.08 (1.72 to 2.53) <0.001 1.88 (1.32 to 2.66) <0.001
Diastolic heart dysfunction 1.63 (1.42 to 1.88) <0.001 1.47 (1.07 to 2.03) 0.018
Lung fibrosis (X-ray or HRCT) 2.03 (1.80 to 2.28) <0.001 1.27 (0.93 to 1.74) 0.138
Anti-topo I antibodies 1.43 (1.24 to 1.58) <0.001 1.11 (0.82 to 1.51) 0.509
Diffuse cutaneous subset 1.40 (1.24 to 1.58) <0.001 0.88 (0.64 to 1.21) 0.432
Bold typeface highlights the baseline covariate of interest, HDU.
Cox proportional hazards analysis adjusted only for age and gender (left) and for age, gender and all clinically important covariates (right).
DLCO<80%, lung CO diffusion <80% predicted; HDU, history of digital ulcers at baseline; HRCT, high resolution CT.
Table 2 Predictors of observed active digital ulcers (DUs) and of reported recent DUs (since previous visit) at prospective visits
Covariate (at baseline)
Active DUs Reported recent DUs
HR (95% CI)
Analysis adjusted




age, gender and all
listed covariates p Value
HR (95% CI)
Analysis adjusted




age, gender and all
listed covariates p Value
HDU 2.60 (2.19 to 3.08) <0.001 2.41 (1.91 to 3.03) <0.001 3.59 (3.23 to 3.99) <0.001 3.23 (2.78 to 3.74) <0.001
Anti-topo I antibodies 2.09 (1.76 to 2.48) <0.001 1.78 (1.39 to 2.28) <0.001 1.81 (1.62 to 2.01) <0.001 1.41 (1.20 to 1.66) <0.001
Joint contractures 2.15 (1.81 to 2.56) <0.001 1.53 (1.20 to 1.94) <0.001 2.04 (1.83 to 2.27) <0.001 1.38 (1.18 to 1.61) <0.001
Elevated US-PAPs 1.52 (1.22 to 1.86) <0.001 1.37 (1.05 to 1.81) 0.023 1.49 (1.30 to 1.70) <0.001 1.41 (1.17 to 1.69) <0.001
DLCO<80% predicted 1.61 (1.26 to 2.06) <0.001 1.29 (1.00 to 1.66) 0.055 1.66 (1.48 to 1.85) <0.001 1.08 (0.92 to 1.27) 0.349
Diffuse cutaneous subset 1.65 (1.38 to 1.97) <0.001 1.15 (0.89 to 1.49) 0.282 1.61 (1.26 to 2.06) <0.001 1.22 (1.02 to 1.44) 0.024
Bold typeface highlights the baseline covariate of interest, HDU.
Cox proportional hazards analysis adjusted only for age and gender (left column for each outcome) and for age, gender and all clinically important covariates (right column for each
outcome).
DLCO, lung CO diffusion; Elevated US-PAPs, a systolic pulmonary arterial pressure >40 mm Hg as measured by power Doppler heart ultrasound examinationl; HDU, history of digital
ulcers at baseline.
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most important and the most easily evaluable inclusion criterion
to define high risk of DUs during follow-up. Another conclusion
is that HDU-positive patients would benefit of vasoactive treat-
ment such as prostanoids and endothelin receptor blockers as
prevention for DUs reoccurrence, especially in the cold season,
while HDU-negative patients would have less benefit.
Our results also show that HDU is predictive for overall car-
diovascular events including new DUs, elevated US-PAPs and
decreased LVEF, thus highlighting the severe prognosis indicated
by HDU. As recently shown by Bruni et al,5 DUs appear to be a
sentinel sign for internal organ involvement and as such for a
worse disease course even in very early SSc. These findings
strengthen the concept of a vascular phenotype of SSc, encom-
passing peripheral vasculature and organ microcirculation
involvement.13 It may seem surprising that in multivariable ana-
lysis HDU was not predictive for severely decreased DLCO,
while being a predictor of elevated US-PAPs; the most likely
explanation is that we have used a rather strict definition for the
severely decreased DLCO (<40% than predicted), while the
definition for increased US-PAPs set a more lenient threshold
for abnormal PAP.
Finally, our study found that HDU is an independent pre-
dictor of a poorer survival. There are several studies on predic-
tors of death in patients with SSc, but only a single-centre
cohort study found that DUs were associated with a poorer
prognosis in terms of survival.14 Noteworthy, our model
includes as independent covariates next to HDU the baseline
parameters DLCO and proteinuria, demonstrated by Bryan
et al15 to be, next to age, gender and ESR, the most important
predictors on survival.16 The Bryan model was intended as a
clinical tool to predict survival and therefore is as simple as pos-
sible, while our model was focused on HDU and therefore we
included all the covariates that were potentially significant (on
clinical judgement). Similarly, Tyndall et al analysed the mortal-
ity of patients with SSc in the EUSTAR cohort and identified the
following independent risk factors for death: proteinuria, an
elevated US-PAPs, FVC <80% of normal, the presence of dys-
pnoea on exertion, a reduced DLCO, an elevated age at SSc
onset and a high mRSS. The statistical analysis of this study
used the same methods as in our present article, and although
in univariable analysis a HDU at inclusion was associated with
decreased survival (HR 1.61, p<0.001), this was no longer
Table 4 Predictors of overall cardiovascular events, defined as a composite outcome resulting of the occurrence of any of the following:





only for age and gender p Value
HR (95% CI)
Analysis adjusted for age,
gender and all listed covariates p Value
HDU 2.12 (1.48 to 3.03) <0.001 3.56 (2.26 to 5.62) <0.001
Joint contractures 2.96 (2.09 to 4.20) <0.001 1.82 (1.10 to 3.00) 0.019
Dyspnoea (clinically significant) 2.06 (1.24 to 3.41) 0.005 2.02 (0.93 to 4.38) 0.076
Diastolic heart dysfunction 2.06 (1.26 to 3.39) 0.004 1.53 (0.88 to 2.65) 0.133
Lung function restrictive defect 1.89 (1.25 to 2.84) 0.002 1.30 (0.72 to 2.35) 0.386
DLCO <80% predicted 1.42 (0.95 to 2.12) 0.085 1.64 (1.04 to 2.58) 0.033
Lung fibrosis (X-ray or HRCT) 1.45 (0.98 to 2.15) 0.061 0.72 (0.41 to 1.25) 0.240
Anti-topo I antibodies 1.56 (1.07 to 2.27) 0.021 1.34 (0.77 to 2.34) 0.302
Diffuse cutaneous subset 1.89 (1.33 to 2.70) <0.001 1.08 (0.62 to 1.87) 0.791
Bold typeface highlights the baseline covariate of interest, HDU.
Cox proportional hazards analysis adjusted only for age and gender (left) and for age, gender and all clinically important covariates (right).
HDU, history of digital ulcers.








all listed covariates p Value
HDU 2.02 (1.67 to 2.43) <0.001 1.53 (1.16 to 2.02) 0.003
Dyspnoea (clinically significant) 3.25 (2.68 to 3.96) <0.001 1.59 (1.17 to 2.15) 0.003
Lung function restrictive defect 3.39 (2.78 to 4.11) <0.001 1.59 (1.13 to 2.23) 0.008
DLCO <80% predicted 3.76 (2.50 to 5.65) <0.001 2.07 (1.31 to 3.28) 0.002
Elevated US-PAPs 3.54 (2.92 to 4.30) <0.001 2.21 (1.65 to 2.96) <0.001
Diastolic heart dysfunction 2.03 (1.65 to 2.51) <0.001 1.34 (1.00 to 1.79) 0.052
Lung fibrosis (X-ray or HRCT) 2.69 (2.21 to 3.28) <0.001 0.92 (0.65 to 1.29) 0.612
Renal crisis history 2.90 (1.87 to 4.50) <0.001 2.03 (1.13 to 3.65) 0.018
Proteinuria 3.50 (2.69 to 4.54) <0.001 2.09 (1.44 to 3.04) <0.001
Diffuse cutaneous subset 2.48 (2.05 to 3.00) <0.001 1.64 (1.19 to 2.25) 0.002
Anti-topo I antibodies 2.19 (1.81 to 2.66) <0.001 1.26 (0.93 to 1.70) 0.139
Bold typeface highlights the baseline covariate of interest, HDU.
Cox proportional hazards analysis adjusted only for age and gender (left) and for age, gender and all clinically significant covariates (right).
Elevated US-PAPs, a systolic pulmonary arterial pressure >40 mm Hg defined by power Doppler heart ultrasound examination.
DLCO <80%, lung CO diffusion <80% predicted; HDU, history of digital ulcers at baseline; HRCT, high resolution CT.
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significant in the multivariable model.10 However, it is not sur-
prising that our study, with a larger population and a threefold
longer follow-up, could identify more risk factors for death.
Comparing the HRs of the various predictors of death in the
multivariable model, it is of interest that an HDU has a prognos-
tic value in regard to survival similar with that of dcSSc subset
and of a decreased FVC and stronger than that of ATA.
The EUSTAR cohort is impressively large and there is no doubt
that cohort studies have significant strengths: they can be used to
study high-risk patients even before they develop certain manifesta-
tions, several outcomes can be studied for each exposure, and statis-
tical modelling can be applied. But such cohorts also have limitations
like missing data and loss to follow-up.17 In our study, for example,
many missing values for baseline ESR (>50% of the patients) made
us decide to not include ESR as a covariate in the Cox models.
Furthermore, in order to allow for a minimum of 3 years of
follow-up, we have selected from the EUSTAR cohort only
patients enrolled before 1 January 2009 and therefore the base-
line data are derived from the original MEDS and not from
MEDS online data. For this reason, as original MEDS include
only few numerical variables (such as the mRSS and DLCO as a
percentage of the predicted value), and do not record medica-
tion, we have not been able to define outcomes by a variation
from baseline (with the exception of skin worsening), nor could
we adjust for treatment. We have tried to overcome this issue by
defining ‘strong’ outcomes that are independent of the baseline
value of the respective parameter—for example, FVC <50% of
the predicted value, at any visit.
Another limitation is the fact that in the EUSTAR database
the presence of ‘baseline HDU’ has been based on patient-
reported data only, and there is no distinct recording for
different categories of DUs (ischaemic, traumatic or related to
calcinosis). Recently, a clinical evidence-based classification of
DUs has been proposed but our baseline data, recorded before
2009, are not detailed accordingly.18 Also, we would have
found useful to include nailfold capillaroscopic pattern at base-
line as a covariate in the multivariable models for new DUs, as
it has been recently shown that a decreased capillary density is
predictive for DUs,19 but for the majority of the patients base-
line capillaroscopy data were not available.
In our cohort, average disease duration at baseline is over
8 years, showing that the majority of cases are not early.
However, this is what we frequently encounter in clinical prac-
tice, so reported HDU remains an important item not to be for-
gotten in history taking, and useful in decision making in regard
to treatment.
Figure 1 The influence of a history of digital ulcers (DUs) at presentation on several outcomes: (A) presence of active DUs at prospective visits; (B)
reported recent DUs (since previous visit) at prospective visits; (C) overall cardiovascular events, defined as a composite outcome resulting of the
occurrence of any of the following: reported history of DUs occurring after any previous visit, systolic pulmonary arterial pressure >40 mm Hg by
power Doppler heart ultrasound, or an LVEF <50%; and (D) all-cause mortality (n=3196 patients with SSc). Kaplan–Meier survival plots, all p<0.001
by the log-rank test.
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The number of patients who developed US-PAPs >40 mm Hg
or LV dysfunction was much lower than that of patients with
recent or active DUs at prospective visits, and the multivariable
Cox model on cardiovascular outcomes, including contractures
as an independent covariate, suggests that new DUs are what
this model mainly predicts. Further studies with more detailed
baseline and follow-up data on cardiovascular outcomes are
thus warranted to assess the predictive value of HDU for the
development of cardiac and vascular complications.
The relationship between HDU at presentation and decreased
survival, as suggested by our results, remains to be confirmed in
studies with more detailed data on mortality. As we lacked infor-
mation on the cause of death and this was not defined as
SSc-related or non-SSc related in a large percentage of cases, we
have not attempted to develop this analysis here.
In conclusion, our data demonstrate that in patients with SSc,
HDU is a risk factor for more severe disease, predicting the
occurrence of new DUs, new cardiovascular events and even a
poorer survival. Reported HDU should prompt the physician to
a careful clinical assessment, management and follow-up of the
patient.
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